Memantine. Poor evaluation and uncertain benefit in Alzheimer's disease

Prescrire International

Volumn 12, Issue 68, 2003, Pages 203-205

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ABDOMINAL PAIN; AGGRESSIVENESS; AGITATION; ALZHEIMER DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFUSION; DIARRHEA; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG MARKETING; DRUG METABOLISM; DRUG RESPONSE; DRUG SURVEILLANCE PROGRAM; DYSKINESIA; FATIGUE; GASTROINTESTINAL DISEASE; GERMANY; HALLUCINATION; HEADACHE; HUMAN; HYPERTENSION; MULTIINFARCT DEMENTIA; NAUSEA AND VOMITING; NERVOUSNESS; NEUROLOGIC DISEASE; NONHUMAN; PRURITUS; REFERENCE VALUE; RISK BENEFIT ANALYSIS; SEIZURE; SIDE EFFECT; TREMOR; VERTIGO; CLASSIFICATION; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG COMBINATION; EUROPE; EVALUATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNITED STATES;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DEMENTIA, VASCULAR; DRUG APPROVAL; DRUG THERAPY, COMBINATION; EUROPE; EVALUATION STUDIES; HUMANS; INDANS; MEMANTINE; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; UNITED STATES;

EID: 0344445506     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Gauthier S "Advances in pharmacotherapy of Alzheimer's disease" CMAJ 2002; 166 (5): 616-623.
2. Le DA and Lipton SA "Potential and current use of N-methyl-D-aspartate (NMDA) receptor antagonists in diseases of aging" Drugs Aging 2001; 18 (10): 717-724.
3. The European Agency for the Evaluation of Medicinal Products - Committee for Proprietary Medicinal Products - European Public Assessment Report (EPAR) "Ebixa". London 13 December 2002: 64 pages.
4. "Forest withdraws memantine US NDA" Scrip 2002; (2785): 26.
5. o" (mémantine) - Dossier technique" 6 February 2003: 48 pages.
6. Reisberg B et al. "Memantine in moderate to severe Alzheimer's disease" N Engl J Med 2003; 348: 1333-1341.
7. Wimo A et al. "Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease" Pharmacoeconomics 2003; 21 (5): 1-14.
8. Tariot P et al. "Memantine/donepezil dual-therapy is superior to placebo/donepezil therapy for treatment of moderate to severe Alzheimer's disease" 41st Annual Meeting of the American College of Neuropsychopharmacology December 2002; abstr. 181: 1 page.
9. Winblad B and Poritis N "Memantine in severe dementia: results of the 9M-best study (benefit and efficacy in severly demented patients during treatment with memantine)" Int J Geriatr Psychiatry 1999; 14: 135-146.
10. Prescrire Rédaction "Troubles cognitifs: moindre détection des effets indésirables" Rev Prescrire 2003; 23 (240): 432.
11. Wesemann W et al. "Distribution and metabolism of the potential anti-Parkinson drug memantine in the human" J Neural Transm 1980; (suppl. 16): 143-148.
12. "Memantine hydrochloride" In: "Martindale The Complete Drug Reference" 33rd ed, The Pharmaceutical Press, London 2002: 1174.
13. Orgogozo JM et al. "Efficacy and safety of memantine in patients with mild to moderate vascular dementia" Stroke 2002; 33: 1834-1839.